Currently, PARP inhibitors have demonstrated significant potential in treating breast cancer, ovarian cancer, pancreatic cancer, and prostate cancer, particularly when combined with radiation therapy; this combination markedly enhances therapeutic efficacy by promoting DSBs accumulation within tumors (Benafif and Hall, 2015). Here, PARP1 is linked to familial pancreatic carcinoma.